Sign up to access all valuation multiples
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
2012
55K+
LTM Revenue $59.8B
LTM EBITDA $26.2B
$464B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
As of September 2025, AbbVie reported last 12-month revenue of $59.8B and EBITDA of $26.2B.
In the same period, AbbVie generated $50.4B in LTM gross profit and $19.6B in net income.
See AbbVie valuation multiples based on analyst estimatesIn the most recent fiscal year, AbbVie reported revenue of $56.3B and EBITDA of $14.9B.
AbbVie expects next 12-month revenue of XXX and NTM EBITDA of XXX
See AbbVie valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $59.8B | XXX | $56.3B | XXX | XXX | XXX |
| Gross Profit | $50.4B | XXX | $39.4B | XXX | XXX | XXX |
| Gross Margin | 84% | XXX | 70% | XXX | XXX | XXX |
| EBITDA | $26.2B | XXX | $14.9B | XXX | XXX | XXX |
| EBITDA Margin | 44% | XXX | 26% | XXX | XXX | XXX |
| EBIT | $26.7B | XXX | $11.9B | XXX | XXX | XXX |
| EBIT Margin | 45% | XXX | 21% | XXX | XXX | XXX |
| Net Profit | $19.6B | XXX | $4.3B | XXX | XXX | XXX |
| Net Margin | 33% | XXX | 8% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $61.6B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
AbbVie has current market cap of $400B, and EV of $464B.
As of October 16, 2025, AbbVie's stock price is $226.
See AbbVie trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $464B | $400B | XXX | XXX | XXX | XXX | $10.43 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAbbVie's trades at 8.2x EV/Revenue multiple, and 31.1x EV/EBITDA.
See valuation multiples for AbbVie and 15K+ public compsAs of October 16, 2025, AbbVie has market cap of $400B and EV of $464B.
Equity research analysts estimate AbbVie's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
AbbVie has a P/E ratio of 20.4x.
| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $400B | XXX | $400B | XXX | XXX | XXX |
| EV (current) | $464B | XXX | $464B | XXX | XXX | XXX |
| EV/Revenue | 7.8x | XXX | 8.2x | XXX | XXX | XXX |
| EV/EBITDA | 17.7x | XXX | 31.1x | XXX | XXX | XXX |
| EV/EBIT | 17.4x | XXX | 39.0x | XXX | XXX | XXX |
| EV/Gross Profit | 9.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 20.4x | XXX | 93.4x | XXX | XXX | XXX |
| EV/FCF | 26.9x | XXX | 26.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAbbVie's last 12 month revenue growth is 9%
AbbVie's revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $0.5M for the same period.
AbbVie's rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
AbbVie's rule of X is 66% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for AbbVie and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 44% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | 25% | XXX | XXX | XXX |
| Rule of 40 | 40% | XXX | 35% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 66% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 23% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 49% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
AbbVie acquired XXX companies to date.
Last acquisition by AbbVie was XXXXXXXX, XXXXX XXXXX XXXXXX . AbbVie acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was AbbVie founded? | AbbVie was founded in 2012. |
| Where is AbbVie headquartered? | AbbVie is headquartered in United States of America. |
| How many employees does AbbVie have? | As of today, AbbVie has 55K+ employees. |
| Who is the CEO of AbbVie? | AbbVie's CEO is Mr. Robert A. Michael. |
| Is AbbVie publicy listed? | Yes, AbbVie is a public company listed on NYS. |
| What is the stock symbol of AbbVie? | AbbVie trades under ABBV ticker. |
| When did AbbVie go public? | AbbVie went public in 2012. |
| Who are competitors of AbbVie? | Similar companies to AbbVie include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of AbbVie? | AbbVie's current market cap is $400B |
| What is the current revenue of AbbVie? | AbbVie's last 12 months revenue is $59.8B. |
| What is the current revenue growth of AbbVie? | AbbVie revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of AbbVie? | Current revenue multiple of AbbVie is 7.8x. |
| Is AbbVie profitable? | Yes, AbbVie is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of AbbVie? | AbbVie's last 12 months EBITDA is $26.2B. |
| What is AbbVie's EBITDA margin? | AbbVie's last 12 months EBITDA margin is 44%. |
| What is the current EV/EBITDA multiple of AbbVie? | Current EBITDA multiple of AbbVie is 17.7x. |
| What is the current FCF of AbbVie? | AbbVie's last 12 months FCF is $17.3B. |
| What is AbbVie's FCF margin? | AbbVie's last 12 months FCF margin is 29%. |
| What is the current EV/FCF multiple of AbbVie? | Current FCF multiple of AbbVie is 26.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
